Business Wire

LG Chem Life Sciences Announces First Participant Dosed in First-in-Human Study of SSAO Inhibitor LG00303174 in the United States

Share

LG Chem Life Sciences (“LG Chem”) today announced the first healthy adult volunteer has been safely dosed in the phase I study of LG00303174 being run in the US.

LG Chem licensed LG00303174 (TT-01025) from TransThera Biosciences Co. Ltd. (“TransThera”), a clinical-stage biotechnology company based in Nanjing, China. LG Chem had entered into an exclusive license agreement with TransThera in August 2020 to research, develop, manufacture, and commercialize LG00303174 in the world except China and Japan.

LG00303174 is a potential best-in-class novel SSAO/VAP-1 inhibitor, currently being developed for the treatment of chronic inflammatory diseases, including non-alcoholic steatohepatitis (NASH). The phase 1 study is currently being conducted within the U.S. and approximately 64 subjects are expected to be enrolled.

“The commencement of this study is a significant landmark for LG Chem as we are determined to address the clear unmet needs of those with metabolic disease,” said Adam Benson, Director of Clinical Development of LG Chem Life Sciences Innovation Center in Cambridge, MA. “NASH to this day remains an elusive target. We feel strongly that LG00303174 has shown, in pre-clinical models, to have a strong safety profile, and as an oral therapy, has the potential to address a clear need in a disease that is becoming increasingly burdensome to our healthcare system.”

Dr. Frank Wu, CEO of TransThera, commented: “We congratulate LG Chem team on the rapid implementation of FIH trial in the United States, which marks a key milestone for this collaboration program.”

According to Dr. Jeewoong Son, President of LG Chem Life Sciences in Seoul, Korea, the fast and efficient implementation of this phase 1 study “is a testament to our clinical development capabilities of the LG Chem Life Sciences Innovation Center in Cambridge as a center of excellence to enrich and forward our development pipeline.”

About LG Chem Life Sciences

LG Chem Life Sciences is a business division within LG Chem, engaged in the development, manufacturing, as well as commercializing pharmaceutical products globally. LG Chem Life Sciences seeks to expand and make global presence by focusing on key core therapeutic areas of Immunology, Oncology, and Metabolic Diseases (specifically, diabetes and related metabolic diseases). To achieve such, its strategy is to actively pursue global collaboration encompassing from asset-centric to strategic investment and collaboration.

LG Chem Life Sciences Innovation Center: innovation.lgchem.com

About TransThera Biosciences

TransThera Biosciences is a clinical-stage biotechnology company dedicated to developing innovative therapeutics to target diseases with major unmet medical needs via internal research platform and open innovation. TransThera's current portfolio covers therapeutic areas such as oncology, cardiovascular, and inflammatory diseases. For more information, please visit www.transtherabio.com.

Contact information

Media (Jiin Chung): media.cbl@lgchem.com
General Inquiries: contact.cbl@lgchem.com
Partners: partners.cbl@lgchem.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

L&T Technology Services Selected by Airbus for Skywise Partner Programme25.2.2021 08:04:00 CETPress release

L&T Technology Services (NSE: LTTS), a leading global pure-play engineering services company, announced that it has been selected by Airbus to provide technology and digital engineering solutions for Airbus’ Skywise platform as part of the ‘Skywise Partner Programme’. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210224006261/en/ Abhishek Sinha, Chief Operating Officer and Board Member LTTS with Rémi Maillard, President & Managing Director, Airbus India & South Asia, commemorate LTTS joining the Skywise Partner Program (Photo: Business Wire) With more than 130 airlines around the world already connected to Skywise, the platform is playing a very important part in enabling and accelerating digital transformation of the aviation sector as a whole. LTTS will support the airlines in the development of complex workflows, creation of new interfaces between their existing information systems and Skywise and also provide assistance

Ecoppia Strengthens Its Presence in the Middle East with a first Project in Egypt25.2.2021 08:00:00 CETPress release

Ecoppia (TASE:ECPA), the pioneer and world leader in robotic solutions for photovoltaic solar, announced today a new project in one of the worlds’ largest solar parks in BenBan, Egypt. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210224005973/en/ Ecoppia's light-weighted T4 solution, designed especially for Single Axis trackers. Completely autonomous, water-free, and energy independent. (Photo: Business Wire) BenBan solar park, located near the southern Egyptian city of Aswan, has a total capacity of 1,650 MWp corresponding to an annual production of approximately 3.8 TW, and is spread across nearly 40 km. While enjoying very high radiation rates, the facility also suffers from major soiling and desert sands, requiring frequent cleaning to ensure steady and optimal production. Ecoppia’s robotic solutions were proven to be extremely effective, cleaning nearly 10 million solar panels every night in harsh climatic conditions,

SES S.A.: Full Year 2020 Results25.2.2021 07:30:00 CETPress release

SES S.A. announces financial results for the year ended 31 December 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210224006241/en/ SES S.A.: Full Year 2020 Results Third successive year delivering EBITDA outlook despite challenging COVID-19 environment in 2020 Growth engine Networks revenue +5% YOY(1,2), or +27% since 2017, and Video revenue of €1,108 million in line with expectations Adjusted EBITDA(3) of €1,152 million delivered within pre-COVID-19 financial outlook and at high end of mid-year outlook Strong net cash generated from operations of €1,049 million representing 97% of reported EBITDA Commitment to disciplined financial policy and shareholder returns Solid cash flow generation driving €505 million YOY debt reduction and lowest leverage ratio(4) (of 2.97 times) over the past 5 years Proposed 2020 dividend of €0.40 per A-share consistent with commitment to maintain a minimum base dividend of €0.40 On track

SES Extends Long-Term Partnership With Sky25.2.2021 07:00:00 CETPress release

Sky UK has extended its contract with SES for satellite capacity in a new agreement that will add over EUR 90 million in secured backlog. This renewal is in addition to capacity already under contract that extends through 2027. By the end of the renewed contract, Sky UK will have been an SES customer continuously for almost four decades, illustrating the strength and value of the partnership to Sky UK’s business in terms of the reliability, performance, high-quality viewing experience and the reach of SES’s satellite services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210224006139/en/ SES Extends Long-Term Partnership With Sky (Photo: Business Wire) As part of the contract, SES will deliver Sky UK’s channels in a mix of standard definition (SD), high definition (HD) and ultra-high definition (UHD) from the 28.2/28.5 degrees East orbital slots to the operator’s subscribers across the United Kingdom and Republic of Irelan

ADVA announces record Q4 2020 results and reports full year 2020 figures25.2.2021 07:00:00 CETPress release

ADVA (ISIN: DE0005103006), a leading provider of open networking solutions for the delivery of cloud and mobile services, reported financial results for Q4 2020 and full year 2020 ended on December 31, 2020. The results have been prepared in accordance with International Financial Reporting Standards (IFRS). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210224005994/en/ Brian Protiva, CEO, ADVA (Photo: Business Wire) Q4 2020 financial summary1 (in thousands of EUR) Q4 Q4 Change Q3 Change 2020 2019 2020 Revenues 140,572 151,135 -7.0% 146,676 -4.2% Pro forma gross profit 54,641 54,633 0.0% 51,930 5.2% in % of revenues 38.9% 36.1% 2.8pp 35.4% 3.5pp Pro forma operating income 14,343 10,333 38.8% 11,053 29.8% in % of revenues 10.2% 6.8% 3.4pp 7.5% 2.7pp Operating income (loss) 13,085 5,438 140.6% 9,768 34.0% Net income 13,249 2,522 425.3% 6,671 98.6% (in thousands of EUR) Dec. 31 Dec. 31 Change Sep. 30 Change 2020 2019 2020 Cash

Protembis Announces Completion of 20 Cases in European CE Mark Study With the ProtEmbo ® Cerebral Protection System25.2.2021 06:15:00 CETPress release

Protembis GmbH, a privately held emerging medical device company, announced today the successful completion of 20 clinical cases in its European regulatory study of the ProtEmbo® Cerebral Protection System. The ProtEmbo® System is an intra-aortic filter device that deflects embolic material away from the brain during transcatheter aortic valve replacement (TAVR). The device is a low profile system which is delivered through the left radial artery, an ideal access site enabling physicians to avoid interference with TAVR equipment, typically delivered through the left femoral artery. Nikos Werner, M.D., Professor of Medicine, Head of Cardiology at the Heart Center Trier, Germany, and Principal Investigator in Germany commented: “Embolic protection in TAVR procedures has been shown to be effective in reducing the ischemic burden in the brain, but physicians look forward to next generation devices that are easy to use, cover all three potential access arteries to the brain, and can be simp

Wipro Marks 25 Years of Partnership With Cisco; Launches Cisco Business Unit25.2.2021 06:00:00 CETPress release

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting, and business process services company, is celebrating the 25th anniversary of its business partnership with Cisco (NASDAQ: CSCO), the worldwide leader in technology that powers the Internet. To commemorate this milestone, Wipro is launching the Cisco Business Unit that will focus on the development and adoption of end-to-end digital transformation solutions leveraging Cisco technologies for customers. This strategic initiative demonstrates Wipro’s commitment to its business relationship with Cisco. Also, it is a growth accelerator for the successful and well-established 360-degree partnership of several years. Over the course of 25 years, Wipro has focused on delivering its transformative service capabilities across Digital, Cloud, Security, and Engineering, which are aligned with Cisco’s operational priorities. Wipro and Cisco co-develop communications, infrastructure, and security

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom